[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-t2dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-t2dm":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,51,86,130,153,198,220,250,271,298,327,353,373,407,429,455,482,507,534,552,574,594,620,647,667],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100627464","phase-3-vitamin-d-and-type-2-diabetes---treat-to-target-100627464",false,"NCT07448974","Vitamin D and Type 2 Diabetes - Treat-To-Target","Vitamin D and Type 2 Diabetes, Treat-To-Target","D2d-TTT","Inclusion Criteria:\n\n1. High-risk prediabetes (\"at high risk for type 2 diabetes\") defined by meeting the following 2 prediabetes criteria established by the American Diabetes Association (ADA) in the 2010 clinical practice guidelines:\n\n   1. Fasting plasma glucose (FPG) 100-125 mg\u002FdL, inclusive\n   2. Hemoglobin A1c (HbA1c) 5.7-6.4%, inclusive\n2. Age 30-74 years, inclusive\n3. Body Mass Index ≥ 23.0 and ≤ 35.0 kg\u002Fm2\n4. Provision of signed and dated written informed consent prior to any study procedures.\n\n   Exclusion Criteria:\n5. History of diabetes (ICD10 diabetes code E08.X through E13.X) or meeting a diabetes glycemic criterion at screening, as defined by the ADA guidelines (FPG ≥ 126 mg\u002FdL or HbA1c ≥ 6.5%).\n6. History (past 2 years) of hyperparathyroidism, symptomatic or asymptomatic (i.e., radiographic) nephrolithiasis or hypercalcemia.\n7. Any medical condition (past 2 years) that in the opinion of the site investigator may increase risk for nephrolithiasis or hypercalcemia during the trial (e.g., sarcoidosis).\n8. If older than 70 years, history (past 1 year) of a fall.\n9. Use of tanning devices within 12 weeks of the baseline visit and unwilling to stop use of tanning devices for the duration of the study.\n\n   Medications and Supplements\n10. Use (past 6 months) of hypoglycemic pharmacotherapy (oral or injectable medication approved by the FDA for type 2 diabetes) for any condition (e.g., prediabetes, diabetes, polycystic ovarian syndrome, MASLD, sleep apnea) or any other medication that may affect glycemia (e.g., hydroxychloroquine)\n11. Current use of medications approved by the FDA for weight management (e.g., incretin receptor agonists) or planned use during the study.\n12. Use of supplements containing vitamin D at total doses higher than 1000 IU\u002Fday within 8 weeks of the baseline visit and unwillingness to limit vitamin D supplementation dosage to no higher than 1000 IU\u002Fday during the study. Because supplements vary widely in vitamin D content (e.g., may include cod liver or cod liver oi), participants will bring all supplements to the site for a review by the research team.\n13. Use of supplements containing calcium at total doses higher than 600 mg\u002Fday within 1 week of the baseline visit and unwillingness to limit calcium supplementation dosage to no higher than 600 mg\u002Fday during the study.\n14. Current use of medications or conditions (e.g., untreated celiac disease) that would interfere with the absorption or metabolism of vitamin D.\n15. Use of an anticonvulsant drug started within 6 months of screening. Stable regimen of anticonvulsants is allowed.\n16. History of intolerance to vitamin D supplements, allergic to any content of the study drug or unwilling to take vitamin D supplements (e.g., someone who eats a vegan diet and would object to the cholecalciferol ingredient which is produced from cholesterol extracted from sheep wool harvested from healthy living sheep).\n\n    Other Medical History\n17. Severe symptomatic cardiovascular disease based on history (unstable angina, dyspnea on exertion, paroxysmal nocturnal dyspnea, arrhythmia, congestive heart failure NYHA class II or higher, claudication)\n18. History (past 1 year) of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft.\n19. History (past 1 year) of cerebrovascular disease (stroke, transient ischemic attack).\n20. Any type of cancer (past 5 years) except for basal cell skin cancer. Prostate cancer (for men over age 55) or well-differentiated thyroid cancer not expected to require treatment (except for suppression with thyroid hormone) over the next 3 years, are not exclusions. People with history of squamous cell cancer of the skin, which was completely excised and with no evidence of metastases, are eligible.\n21. History (past 6 months) of treatment with oral (for \\> 7 days) or intravenous glucocorticoids or disease likely to require oral or intravenous glucocorticoid therapy during the study. Inhaled glucocorticoid use is not an exclusion. Epidural or intra-articular glucocorticoid injections are not exclusions, but study visits need to be conducted at least two weeks after the injection. Persons with adrenal insufficiency treated with physiologic doses of glucocorticoids who are otherwise stable are not excluded.\n22. History (past 1 year) of substance abuse or unstable psychiatric disorder that in the opinion of the site investigator would impede competence or adherence with study procedures or hinder completion of the study or increase risk.\n23. History of bariatric surgery (e.g., Roux-en-Y gastric bypass, gastric sleeve) or planned bariatric surgery in the next 2 years.\n24. Extreme (over 18 hours) intermittent fasting diets because prolonged fasting downregulates CYP2R1 activity.\n25. A life-threatening event within 30 days of screening or currently planned major surgery.\n26. Any other active medical condition (including but not limited to liver disease, wasting illness, HIV, tuberculosis, oxygen-dependent chronic obstructive pulmonary disease, organ transplant, Cushing's syndrome) that in the opinion of the site investigators would interfere with the study objectives, impede competence or adherence with study procedures or increase risk.\n27. Uncontrolled hypertension (systolic blood pressure \\> 160 mm Hg or diastolic blood pressure \\> 100 mm Hg).\n28. Poor venous access.\n\n    Laboratory Evaluation\n29. Serum liver transaminase higher than 3 times the normal range for the clinical site's laboratory, within 18 months of screening.\n30. Anemia (hematocrit \\\u003C 32 for women, \\\u003C 36 for men), whole blood transfusion (within 18 months of screening) or chronic requirement, whole blood donation (within 3 months of screening) or other condition (hemolysis, hemoglobinopathy) rendering HbA1c results unreliable as indicator of chronic glycemia. Participants who donate platelets are not excluded.\n31. Low platelet count (\\\u003C 100,000) within 18 months of screening.\n32. Chronic kidney disease, defined as estimated glomerular filtration rate \\[GFR\\] \\\u003C 50 mL\u002Fmin per 1.73 m2 from creatinine level and GFR calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations that omit race within 18 months of screening.\n33. Hypercalcemia, defined as serum calcium concentration ≥ upper limit of normal within 18 months of screening.\n34. Hypercalciuria, defined as spot urine (morning void) calcium-creatinine ratio \\> 0.275 within 18 months of screening.\n35. Baseline serum 25(OH)D level greater than 100 ng\u002FmL.\n\n    Other\n36. Participation (within 30 days of screening) in another interventional research study, and unwillingness to refrain from participating in another intervention study during the study.\n37. Previous randomization in the study. Participants who did not qualify after screening may be screened again if the prior reason for exclusion has been addressed (e.g., high blood pressure is treated).\n38. Any other reason that in the opinion of the site investigator would interfere with the study objectives, impede adherence with study procedures or hinder completion of the study or increase risk.\n\n    Women only\n39. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to become pregnant in the next 2 years. History of gestational diabetes is not an exclusion criterion.\n40. Currently breastfeeding.\n41. Use of oral contraceptives or menopausal hormone therapy started within 3 months of baseline. .\n\n    Continuous Glucose Monitoring specific\n42. Regular use of personal CGM and unwillingness to refrain from using personal CGM for the duration of the study.\n43. Use of hydroxyurea or regular use of high doses of acetaminophen (may impact CGM).\n44. Extensive skin changes (e.g., skin breakdown, rash) making CGM sensor use problematic.\n45. Significant skin sensitivity to adhesive (making CGM sensor unfeasible).","ALL","30 Years","74 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","This study tests whether taking a weekly dose of vitamin D, with the dose adjusted to reach a target blood vitamin D level, can help control blood sugar levels in adults at high risk of developing type 2 diabetes (prediabetes).\n\nResearch suggests that vitamin D may play a role in blood sugar control. The goal of this study is to see whether adjusting the dose of vitamin D to reach a specific blood vitamin D level improves blood sugar control compared with a placebo (a look-alike pill without vitamin D).\n\nOne hundred adults aged 30 to 74 with prediabetes will take part. Participants will be randomly assigned (by chance) to receive either weekly vitamin D supplements or a placebo. Neither the participants nor the research team will know which group a participant is in during the study.\n\nParticipants in the vitamin D group will start with one specific dose. After three months, a blood test will be used to decide whether the dose should stay the same or be increased to reach the target vitamin D level. Participants in the placebo group will continue taking the placebo each week.\n\nAll participants will be followed for about 18 months. During the study, they will attend scheduled study visits, have blood tests, and wear a continuous glucose monitor, a small device that measures blood sugar levels throughout the day and night. The research team will also make periodic phone calls to check on health changes, medication use, and study participation.\n\nThe main outcome of the study is the proportion of time that the participants' blood sugar levels remains in a healthy range.",[29,30],"Prediabetes","Type 2 Diabetes (T2DM)",[32,33,34,35,36,37],"vitamin D","cholecalciferol","continuous glucose monitoring","diabetes prevention","prediabetes","type 2 diabetes","RECRUITING","2026-08-14",{"date":41,"type":42},"2026-08-18","ACTUAL",{"date":44,"type":42},"2026-08-04",{"date":46,"type":23},"2031-03",{"name":48,"class":49},"Tufts Medical Center","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":50},"100614529","cgm-based-glycemic-analysis-after-esi-100614529","NCT07280780","CGM-Based Glycemic Analysis After ESI","Continuous Glucose Monitoring-Based Evaluation of Glycemic Fluctuations Following Epidural Steroid Injections: A Comparative Study by Diabetic Status","CGMSteroid","Inclusion Criteria:\n\n* Adults aged 20 to 60 years.\n* Patients scheduled for cervical or lumbar epidural steroid injection at the pain clinic.\n* Patients capable of understanding and using a Continuous Glucose Monitoring (CGM) device.\n\nExclusion Criteria:\n\n* Patients currently taking or administering steroid medications.\n* Patients with Type 1 Diabetes Mellitus.\n* Patients with Cushing's disease.\n* Patients who have received an epidural steroid injection within the last 3 months.\n* Patients with a known allergy to contrast media.\n* Patients taking anticoagulants or antiplatelet agents.\n* Patients unable to use a Continuous Glucose Monitoring (CGM) device.","20 Years","60 Years",{"count":62,"type":23},36,"OBSERVATIONAL","The goal of this clinical study is to learn how blood glucose levels change after an epidural steroid injection (ESI) with dexamethasone in adults. It will specifically compare the glycemic response between patients with type 2 diabetes and those without diabetes.\n\nThe main questions it aims to answer are:\n\nDoes the injection cause higher or longer-lasting blood glucose elevation in diabetic patients compared to non-diabetic patients? How do the mean glucose level and Time in Range (TIR) change after the injection in both groups?\n\nResearchers will compare a Type 2 Diabetes group to a Non-Diabetes group to see the differences in glycemic fluctuations using a continuous glucose monitoring (CGM) device.\n\nParticipants will:\n\n* Wear a small CGM sensor on their arm for about 15 days to monitor blood glucose levels continuously\n* Receive an epidural steroid injection containing 5 mg of dexamethasone on Day 3\n* Visit the clinic 3 times (Day 1, Day 3, and Day 15) for sensor attachment, the injection procedure, and data collection",[30,66,67,68,69],"Hyperglycemia","Radicular Pain","Spinal Stenosis","Intervertebral Disc Herniation",[71,72,73,74,75],"epidural steroid injection","Continuous Glucose Monitoring","Dexamethasone","Glycemic Variability","Time in range","NOT_YET_RECRUITING","2026-08-11",{"date":79,"type":42},"2026-08-12",{"date":81,"type":23},"2026-08-05",{"date":83,"type":23},"2026-12-31",{"name":85,"class":49},"Korea University Anam Hospital",{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":100,"conditions":101,"keywords":110,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":50},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per day.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","45 Years","70 Years",{"count":97,"type":23},216,[99],"NA","Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[102,103,104,105,106,107,108,109,30],"Type 2 Diabetes","Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes Mellitus",[111,112,113,114,37,115,36,116,117,118,119,120],"chronic disease","diabetes","diabetes mellitus","type II diabetes","pre-diabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine","2026-08-03",{"date":123,"type":42},"2026-08-06",{"date":125,"type":42},"2025-10-14",{"date":127,"type":23},"2027-02-16",{"name":129,"class":49},"University of Pennsylvania",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":50},"100650115","phase-3-a-study-of-bgm0504-in-early-t2dm-with-obesity-100650115","NCT07743983","A Study of BGM0504 in Early T2DM With Obesity","A Randomized, Open-Label, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety, and Diabetes Remission of BGM0504 Injection Compared With Semaglutide Injection in Early-Stage Chinese Type 2 Diabetes Mellitus Patients With Obesity and Inadequate Glycemic and Weight Control Despite Diet and Exercise Intervention（BRIGHT-1）","Inclusion Criteria:\n\n* ○ Have been diagnosed with type 2 diabetes mellitus (T2DM)， disease duration ≤5 years, treatment naïve with ≥8 weeks diet\u002Fexercise, or off antidiabetic therapy ≥8 weeks prior to screening.\n\n  * BMI 28.0-35.0 kg\u002Fm² at screening, with stable weight (±5%) for 3 months prior to screening.\n  * Have HbA1c between ≥7.5% and ≤10.5% at screening.\n  * FPG ≤15.0 mmol\u002FL at screening.\n  * If hypertensive: SBP \\\u003C180 mmHg and DBP \\\u003C110 mmHg at enrollment, on stable (≥2 weeks) ≤2 antihypertensives, or no medication with diet\u002Fexercise ≥4 weeks.\n  * Willing to comply with protocol, use effective contraception, and provide informed consent.\n\nExclusion Criteria:\n\n* ● Previous diagnosis of type 1 diabetes, special type diabetes or gestational diabetes.\n\n  * Prior use of antidiabetics or systemic glucocorticoids within 8 weeks, prior GLP-1\u002FGIP\u002FGCG receptor agonists with intolerance\u002Fpoor response, or weight-loss drugs within 3 months.\n  * History of acute\u002Fchronic pancreatitis.\n  * Medullary thyroid carcinoma, MEN 2A\u002F2B, or family history.\n  * Malignancy within 5 years (except treated BCC\u002FSCC, cervical\u002FPSC\u002Fthyroid papillary carcinoma in situ with no recurrence).\n  * Severe cardiac conditions within 6 months: NYHA III\u002FIV HF, unstable angina, MI, CABG\u002Fstent, severe arrhythmias.\n  * Hemorrhagic or ischemic stroke within 6 months.\n  * Severe renal disease or eGFR ≤60 mL\u002Fmin\u002F1.73 m² (CKD-EPI).\n  * Pregnant or lactating woman.\n  * Prior clinical trial participation with investigational drug or device within 3 months.\n  * Other situations that are deemed as inappropriate for participation by investigators.","18 Years","75 Years",{"count":140,"type":23},372,[26],"This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.",[30],"2026-07-29",{"date":44,"type":42},{"date":147,"type":23},"2026-08-30",{"date":149,"type":23},"2028-11-30",{"name":151,"class":152},"BrightGene Bio-Medical Technology Co., Ltd.","INDUSTRY",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":18,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":165,"conditions":166,"keywords":179,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100650085","health-for-hungary-h4h---longitudinal-collection-of-blood-samples-and-corresponding-data-100650085","NCT07743021","Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data","Health for Hungary - Longitudinal Collection of Blood Samples and Corresponding Data for Longterm Evaluation of Innovative Diagnostic Techniques in Subjects Without Clinically Relevant Disorders at Baseline to Institute Molecular Fingerprinting Reference Norms","H4H","Low- and Moderate-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 40 years.\n3. Willingness to fill in the study questionnaire.\n4. No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed.\n5. Willingness to participate in future visits.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Indications of clinically relevant medical conditions in self-reported healthy subjects.\n3. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n4. Any conditions preventing blood-draw.\n5. Vulnerable subjects.\n6. Foreseeable lack of compliance.\n7. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject.\n8. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and \u002F or further pharmaceutical product administration is planned.\n9. Vaccination within the last 14 days.\n\nHigh-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 50 years.\n3. Willingness to fill in the study questionnaire.\n4. Willingness to participate in future visits and medical investigations, the presence of at least 2 of the following 3 risk factors (inclusion criteria #5-7):\n5. Hypertension, receiving antihypertensive treatment.\n6. Dyslipidemia\u002F Hypercholesterolemia (\\>5.2mmol\u002FL total cholesterol level), on or not on statin-treatment.\n7. Active or former smoker, with smoking history of at least 20 pack-years, and\u002For the presence of intermediate lung nodule on prior LDCT testing.\n8. No clinically relevant symptoms as assessed by the investigator; subjects with existing medical conditions may be eligible given that they are symptom free and that treatment of the condition is well documented.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Cardiovascular disease (including obstructive coronary artery disease, peripheral artery disease, aortic aneurysm) or other clinically significant heart disease (congenital, valvular heart disease, cardiomyopathy, heart failure and heart disease requiring ICD \\[implantable cardioverter defibrillator\\] or pacemaker therapy).\n3. Interstitial lung disease or severe COPD (chronic obstructive pulmonary disease) in GOLD stages 3 or 4.\n4. Active cancer or malignant disease with less than 5 years history of remission.\n5. Indications of clinically relevant medical conditions in self-reported healthy subjects, especially if (a) the condition requires regular or constant specialist checkups, or (b) pharmacological therapy indicates the presence of significant NCDs or multimorbidity, i.e., chronic polypharmacy (use of 5 or more medications at enrollment or over the last 6 months), or drug therapy necessitating a specialist input for initiation or management (e.g., combined anti-diabetic treatment with two or more medications).\n6. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n7. Any conditions preventing blood-draw or CT scans.\n8. Vulnerable subjects.\n9. Foreseeable lack of compliance.\n10. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 'High-risk' subjects enrolled in the low- and moderate-risk arm of the H4H study might be reallocated to the high-risk study arm after the first 4-5 visits.\n11. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and\u002For further pharmaceutical product administration is planned.\n12. Vaccination within the last 14 days of sample collection.",true,"40 Years",{"count":164,"type":23},15000,"The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.\n\nIndications Studied:\n\nApparently healthy, symptom-free participants are enrolled and followed up to study the onset of new-onset diseases with special emphasis on non-communicable diseases (NCDs).\n\nStudy Design:\n\nSingle-country, multicenter, prospective, longitudinal survey.\n\nObjectives:\n\nThe study aims to establish reference ranges of blood parameters using routine clinical blood tests and high-information-content methods, including proteomics, metabolomics and the so-called infrared molecular fingerprinting.\n\nThe study also aims to identify novel biomarkers of major non-communicable diseases, including atherosclerotic cardiovascular disease, cancer, diabetes and chronic respiratory disease.",[167,168,169,170,171,172,173,174,175,176,30,29,177,178],"Non-communicable Diseases (NCD)","Neoplams","Cancer","Lung Cancer (NSCLC)","Cardiovascular Diseases (CVD)","Atherosclerotic Cardiovascular Disease (ASCVD)","Peripheral Artery Disease (PAD)","Coronary Artery Disease (CAD)","Stroke (CVA) or TIA","Diabetes Mellitus (DM)","Chronic Respiratory Diseases","Chronic Obstructive Pulmonary Disease (COPD)",[180,181,182,183,184,185,186,187,188,189],"Personalized health","Molecular fingerprints","Longitudinal health monitoring","Early-stage disease detection","Innovative research platforms","Precision care","Proteomics","Metabolomics","in vitro diagnostics","Prevention medicine",{"date":121,"type":42},{"date":192,"type":42},"2021-07-27",{"date":194,"type":23},"2030-12-31",{"name":196,"class":49},"Center for Molecular Fingerprinting Research Nonprofit LLC",33,{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":50},"100604965","salivary-cortisol-and-hypercortisolism-in-type-2-diabetes-100604965","NCT07156370","Salivary Cortisol and Hypercortisolism in Type 2 Diabetes","Study to Explore the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Assess the Correlation Between Salivary Cortisol and Glucose Levels","Inclusion Criteria:\n\n1. Aged between 18 and 80 years.\n2. Meets the definition of difficult to control type 2 diabetes:\n\nHbA1c level between 7.5% and 11.5%, AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND\u002FOR b.) concomitant hypertension requiring 2 or more anti-hypertension medications.\n\nExclusion Criteria:\n\n1. Patients with Type 1 diabetes, new-onset diabetes (\\\u003C1 year duration), or other specific types of diabetes.\n2. History of systemic glucocorticoid use within the last 3 months (inhaled or topical agents are not exclusionary).\n3. Pregnant or lactating.\n4. Presence of severe cardiac, hepatic, renal, or other major organ dysfunction.\n5. History of acute diabetic complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, within the last 3 months.\n6. Presence of diseases that significantly affect metabolism, such as malignancy or autoimmune disorders.\n7. Inability to tolerate adhesive tape, severe skin conditions at the sensor placement site, or presence of a psychiatric illness or cognitive impairment that would interfere with study compliance.\n8. A known diagnosis of Cushing's syndrome, or currently receiving treatment with any of the following: mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, long-acting octreotide, or pasireotide.\n9. Excessive alcohol consumption (defined as \\>14 units per week for males or \\>7 units per week for females).\n10. Severe, untreated sleep apnea.\n11. Night shift workers (defined as being awake between 11:00 PM and 7:00 AM).\n12. Known allergy or severe reaction to dexamethasone.","80 Years",{"count":207,"type":23},500,"The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies. Additionally, the study will evaluate the correlation between salivary cortisol levels and glycemic control.",[210,30],"Hypercortisolism","2026-07-24",{"date":213,"type":42},"2026-07-27",{"date":215,"type":42},"2025-09-11",{"date":217,"type":23},"2027-12-31",{"name":219,"class":49},"Shanghai 6th People's Hospital",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":230,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":249},"100645460","diabetes-glycemic-assessment-in-newly-confirmed-episodes-100645460","NCT07690163","DIabetes GLycemic Assessment in Newly Confirmed Episodes","Evaluation of Continuous Glucose Monitoring Systems for Optimizing Glycemic Control in Patients With Newly Diagnosed Type 2 Diabetes: A Postmarketing Clinical Analysis","DI-GLANCE","Inclusion Criteria:\n\n* Age of 18 years and older.\n* Newly diagnosed Type 2 Diabetes Mellitus according to ADA (American Diabetes Association) criteria (Fasting Plasma Glucose ≥ 7.0 mmol\u002FL, or 2-hour Post-Prandial Glucose ≥ 11.1 mmol\u002FL during OGTT, or HbA1c ≥6.5%).\n* Time since the initial diagnosis of T2D must not exceed 3 months ( less 90 days) at the time of screening.\n* HbA1c level between 6.5% and 9.5% (inclusive) at screening.\n* Patients may be lifestyle-controlled or receiving any stable non-insulin anti-diabetic therapy (including Metformin, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, or Sulfonylureas) as monotherapy or combination therapy.\n* Ability to provide written informed consent and willingness to adhere to the study protocol and follow-up schedule.\n\nExclusion Criteria:\n\n* Diagnosis or suspicion of Type 1 Diabetes, Latent Autoimmune Diabetes in Adults (LADA) (e.g., positive anti-GAD antibodies if tested), or secondary types of diabetes (e.g., pancreatic or drug-induced).\n* Any prior or current use of insulin therapy.\n* Severe microvascular or macrovascular complications (proliferative retinopathy, severe diabetic nephropathy with eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m², diabetic foot ulcers, severe peripheral neuropathy).\n* Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia.\n* History of myocardial infarction, stroke, unstable angina, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI) within the past 6 months.\n* Active malignancy, decompensated heart failure (NYHA Class III or IV), or chronic infectious diseases.\n* Pregnant or breastfeeding women, or women of childbearing potential not using highly effective contraception.\n* Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant.\n* Participation in another clinical study within the last 3 months.",{"count":229,"type":23},80,[99],"This is a prospective, open-label, randomized controlled trial involving 80 adult patients with newly diagnosed T2DM (diagnosed within the last 3 months) recruited at the Bogomolets National Medical University. Participants may be lifestyle-controlled or receiving stable non-insulin anti-diabetic medications. Participants will be randomized in a 1:1 ratio to either the Real-Time Continuous Glucose Monitoring group (CGM group) or the control group (standard Self-Monitoring of Blood Glucose \\[SMBG\\] using conventional glucometers).\n\nThe gathered data will help determine whether the real-time visual feedback provided by CGM systems superiorly improves glycemic variability, optimizes metabolic parameters, and enhances patient adherence to lifestyle interventions and pharmacological treatment compared to conventional SMBG methods in the early stages of T2D.",[30,233,234,235],"Obesity Type 2 Diabetes Mellitus","Obesity & Overweight","Insulin Resistance",[237,34,238,239,37],"obesity","insulin resistance","traditional glycemia self-monitoring","2026-07-11",{"date":242,"type":42},"2026-07-14",{"date":244,"type":23},"2026-07-15",{"date":246,"type":23},"2027-03-31",{"name":248,"class":49},"Nazarii Kobyliak",3,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":257,"targetDuration":259,"studyType":63,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":50},"100647258","cardiovascular-risk-in-t2dm-with-mafld-a-cohort-study-100647258","NCT07706010","Cardiovascular Risk in T2DM With MAFLD: A Cohort Study","A Cohort Study on Cardiovascular Risk in Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-Associated Fatty Liver Disease","Inclusion Criteria:\n\n* 1.Age ≥18 years, male or female;\n\n  2.Meet the diagnostic criteria for type 2 diabetes mellitus (T2DM) according to the Chinese Guideline for the Prevention and Treatment of Type 2 Diabetes (2022 edition), with a confirmed diagnosis for at least 3 months;\n\n  3.Meet the diagnostic criteria for metabolic dysfunction-associated steatotic liver disease (MASLD) according to the \\*Chinese Guideline for the Diagnosis and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (2024 edition)\\*, with preliminary assessment including liver enzymes (ALT\u002FAST), liver ultrasound, and non-invasive fibrosis markers (FIB-4, LSM), and exclusion of other liver diseases;\n\n  4.Willing to participate in this study and provide written informed consent;\n\n  5.Able to cooperate with baseline survey and long-term follow-up (i.e., expected to reside in the study area during the follow-up period, without severe cognitive impairment, movement disorders, or other conditions that would interfere with follow-up).\n\nExclusion Criteria:\n\n* 1.Concomitant other chronic liver diseases: viral hepatitis (hepatitis B, hepatitis C, etc.), alcoholic liver disease (alcohol intake ≥140 g\u002Fweek for males, ≥70 g\u002Fweek for females), autoimmune liver disease, drug-induced liver injury, liver cirrhosis, liver cancer, etc.;\n\n  2.Concomitant severe cardiovascular or cerebrovascular disease, end-stage renal disease (CKD stage 5), malignant tumor, severe infection, etc., with an estimated life expectancy \\\u003C5 years;\n\n  3.Current use of medications that may significantly affect liver metabolism or glucose metabolism (other than routine glucose-lowering, lipid-regulating, or hepatoprotective agents) that cannot be adjusted;\n\n  4.Pregnant or lactating women, or those planning to become pregnant in the near term;\n\n  5.Severe mental illness or cognitive impairment that prevents cooperation with surveys and follow-up;\n\n  6.Refusal to sign informed consent, or inability to comply with study procedures.",{"count":258,"type":23},7000,"5 Years","This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes in patients with T2DM, after excluding the confounding effects of traditional cardiovascular risk factors. Its technical value lies in utilizing prospective follow-up data combined with a multivariable competing risks model to develop and validate a cardiovascular risk prediction and early warning system tailored for Chinese populations with T2DM complicated by MASLD. Clinically, the findings will provide interdisciplinary evidence-based support for endocrinology and cardiology, helping clinicians identify high-risk individuals and prevent cardiovascular events through early intervention targeting hepatic metabolic disorders. This has significant implications for reducing overall mortality among diabetic patients in China and alleviating the public health burden.",[30,262],"Metabolic Dysfunction-Associated Steatotic Liver Disease","2026-07-10",{"date":244,"type":42},{"date":266,"type":23},"2026-07-12",{"date":268,"type":23},"2031-05-29",{"name":270,"class":49},"The Affiliated Hospital of Hangzhou Normal University",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":50},"100645606","effect-of-ajwa-seed-powder-on-hba1c-and-body-composition-in-overweight-and-obese-patients-with-type-2-diabetes-mellitus-100645606","NCT07702097","Effect of Ajwa Seed Powder on HbA1c and Body Composition in Overweight and Obese Patients With Type 2 Diabetes Mellitus","Effect of Ajwa Seed Powder on HbA1c and Body Composition in Overweight and Obese Patients With Type 2 Diabetes Mellitus: A Single-Arm Interventional Stuy","Inclusion Criteria\n\n* Age: 30-50 years\n* Gender: Male\u002Ffemale\n* Body Mass Index (BMI): 25-35 kg\u002Fm²\n* Type 2 diabetes mellitus: HbA1c ≥ 6.5% Exclusion criteria History of alcoholic liver disease or cirrhosis; liver dysfunction based on initial blood tests\n* Patients being treated with insulin\n* High initial levels of serum creatinine (men\\>1.5 mg\u002Fdl; women\\>1.2 mg\u002Fdl)\n* Pregnant\u002Flactating females or women who cannot take proper contraceptive measures\n* Symptoms consistent with peptic ulcer disease or history of peptic ulcers\n* Active cancer patients\n* Severe non-diabetes-related illnesses\n* Patients with heart, liver, or lung failures\n* Patients with blood disorders or on anticoagulant drugs such as warfarin Any other disease as decided by the principal investigator, which might put the safety of the subjects at risk while conducting the test","50 Years",{"count":280,"type":23},30,[99],"The goal of this interventional study (clinical trial) is to check if ajwa seed powder can treat type 2 diabetes mellitus in overweight and and obese patients with type 2 diabetes mellitus including both male and female of the age group between 30-50. The main question is what would be the impact of ajwa seed powder on HbA1c and body composition in overweight and obese patients with type 2 diabetes mellitus which aim to\n\nresult in better glycemic control particular Hba1c, and body composition improvement in type 2 diabetes mellitus patients\n\nParticipants will be asked to consume 4 grams of ajwa seed powder per day",[234,30],[285,286,287,288,289],"Type 2 diabetes mellitus","HbA1c","Ajwa seed powder","Obesity","Body composition","2026-07-09",{"date":242,"type":42},{"date":293,"type":23},"2026-06",{"date":295,"type":23},"2027-06",{"name":297,"class":49},"University of Veterinary and Animal Sciences, Lahore - Pakistan",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":95,"enrollmentInfo":306,"targetDuration":4,"studyType":24,"phases":308,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":249},"100603660","phase-2-triglytza-01-versus-metformin-in-overweight-and-obese-adults-with-type-2-diabetes-and-inadequate-glycaemic-control-despite-metformin-therapy-100603660","NCT07139405","TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy","A Double-Blind, Randomized, Active-Controlled Phase 2a Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TriGlytza®-01 in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy","RESILIENCE-2a","Inclusion Criteria Adults aged 18 to 70 years. Confirmed diagnosis of Type 2 diabetes mellitus. Inadequate glycaemic control while receiving a stable dose of metformin.\n\nInclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* Confirmed diagnosis of Type 2 diabetes mellitus.\n* Inadequate glycaemic control while receiving a stable dose of metformin.\n* HbA1c within the protocol-defined screening range.\n* Body mass index (BMI) 25 to 40 kg\u002Fm².\n* Adequate renal function.\n* Able and willing to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or history of diabetic ketoacidosis.\n* Use of prohibited glucose-lowering medications before screening.\n* Clinically significant renal, hepatic, gastrointestinal, cardiovascular, or other medical conditions that could interfere with study participation or safety.\n* Recent major cardiovascular event or unstable cardiovascular disease.\n* Previous bariatric surgery or recent treatment with anti-obesity medication.\n* Active infection or other uncontrolled medical condition.\n* Pregnant or breastfeeding, or unwilling to comply with protocol-required contraception.\n* Any condition that, in the investigator's opinion, would make participation unsuitable or compromise the study.",{"count":307,"type":23},48,[309],"PHASE2","This Phase 2a, randomized, double-blind, active-controlled study will evaluate the safety, tolerability, and preliminary efficacy of TriGlytza®-01 compared with metformin in adults with Type 2 diabetes inadequately controlled despite metformin therapy. Participants will be randomized to one of three treatment groups and treated for 16 weeks. Safety, glycaemic control, body weight, and other metabolic outcomes will be assessed",[30],[102,313,314,315,316,317],"Diabetes","Metformin","Myopharm","Valsartan","Celecoxcib","2026-07-05",{"date":320,"type":42},"2026-07-08",{"date":322,"type":23},"2026-09-01",{"date":324,"type":23},"2027-12-30",{"name":326,"class":49},"Myopharm Limited",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":337,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":351,"locationsCount":50},"100645029","hcc-risk-and-monitoring-in-patients-with-type-2-diabetes-100645029","NCT07675187","HCC Risk and Monitoring in Patients With Type 2 Diabetes","Hepatocellular Carcinoma Risk Assessment and Surveillance in Patients With Type 2 Diabetes","GAAD-DM","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosed with type 2 diabetes mellitus and clinically followed with regular outpatient visits.\n* FIB-4 index greater than 2.67 (calculated based on AST, ALT, and platelet count within the past 6 months).\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* HBsAg positive.\n* Anti-HCV positive and HCV RNA positive (patients with anti-HCV positive but negative HCV RNA are still eligible).\n* Prior history of hepatobiliary malignancies.\n* Undergoing regular abdominal ultrasound screening more than once per year.\n* Established diagnosis of liver cirrhosis via abdominal ultrasound or clinical evaluation.\n* Diagnosed with or treated for any malignancy within the past 2 years.\n* Women of childbearing potential or pregnant women.\n* Thrombocytopenia secondary to hematologic disorders.\n* Known history of human immunodeficiency virus (HIV) infection.\n* Concomitant use of medications that may interfere with PIVKA-II assay results (e.g., warfarin, vitamin K).",{"count":336,"type":23},2400,[99],"Liver cancer is a significant malignancy in Taiwan. With the widespread implementation of antiviral therapies, hepatitis B and C-related liver cancer has gradually declined; however, metabolic dysfunction-associated liver cancer continues to increase, particularly among patients with type 2 diabetes mellitus (T2DM) who also present with significant liver fibrosis. Current clinical guidelines lack standardized recommendations for liver cancer screening in this specific population, and data from prospective randomized controlled trials remain scarce.This study is a prospective randomized controlled trial enrolling patients aged 18 years, diagnosed with T2DM, and with a FIB-4 \\> 2.67. Participants will be randomly assigned to either the surveillance group or the standard-care group. The surveillance group will undergo blood tests every 6 months to monitor liver function, AFP, and PIVKA-II, alongside the calculation of the GAAD score. The standard-care group will receive liver function tests every 6 months according to routine clinical practice. Abdominal ultrasound or computed tomography (CT) scans will be arranged by clinicians when clinically indicated. All participants will undergo abdominal ultrasound at baseline and at the end of the third year, with blood samples and clinical data collected periodically. The primary endpoint of this study is the tumor size at the time of liver cancer diagnosis. Secondary endpoints include liver cancer staging, number of liver cancer tumors, liver cancer incidence, the proportion of patients receiving curative treatment, and the degree of liver fibrosis as reflected by changes in FIB-4. This study expects to clarify the clinical benefits of a GAAD score-based surveillance strategy compared to standard care in T2DM patients with high FIB-4 scores, thereby providing evidence-based support for future liver cancer screening strategies and clinical guidelines.",[30,340],"Hepatocellular Carcinoma (HCC)",[102,342,343,344],"Liver Cancer","Surveillance","Prospective Randomized Study","2026-07-02",{"date":347,"type":42},"2026-07-07",{"date":349,"type":23},"2026-07-01",{"date":194,"type":23},{"name":352,"class":49},"National Taiwan University Hospital",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":24,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":50},"100633468","phase-3-evaluate-the-efficacy-and-safety-of-gzr33-injection-in-patients-with-type-2-diabetes-100633468","NCT07527078","Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes","A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Comparing the Efficacy and Safety of GZR33 Injection and Insulin Degludec Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antidiabetic Drugs","Inclusion Criteria:\n\n1. Subjects sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and are able to follow the contraindications and restrictions specified in this protocol.\n2. Male or female, aged ≥18 years at the time of informed consent..\n3. Body mass index (BMI) ≥18.5 and ≤35.0 kg\u002Fm2 at screening.\n4. According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening.\n5. Stable treatment with oral antidiabetic drugs for ≥ 90 days prior to screening.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to ≥ 2 drugs with distinct mechanisms of action, or known hypersensitivity, allergic reactions, or intolerance to the investigational medicinal products or their excipients (glycerol, phenol, metacresol, zinc acetate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide).\n2. Female subjects who are pregnant, lactating at screening, or planning a pregnancy during the trial period.\n3. Confirmed or suspected type 1 diabetes mellitus or specific types of diabetes due to other causes (monogenic diabetes syndrome, cystic fibrosis-related diabetes, pancreatitis-induced diabetes, drug- or chemical-induced diabetes, etc.) prior to screening.\n4. Presence of any diseases that may affect HbA1c testing at screening, such as hemolytic anemia, aplastic anemia, hemoglobinopathy, etc., and in the investigator's judgment unsuitable for participation; or blood donation, blood loss \\> 400 mL, or blood transfusion within 90 days prior to screening.\n5. History of severe cardiovascular and cerebrovascular diseases within 180 days prior to screening.\n6. Significant hepatic or renal dysfunction or active infectious diseases at screening.\n7. Lifestyle (diet, exercise, work circadian rhythm, etc.) expected to change significantly during the trial and affect glycemic control; irregular three-meal intake (e.g., habitual skipping of breakfast); or unwillingness to comply with relevant lifestyle restrictions during the trial.\n8. Any other conditions that, in the investigator's judgment, may compromise subject safety or interfere with trial conduct, progress, or outcome.",{"count":361,"type":23},350,[26],"Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.",[30],"2026-06-29",{"date":349,"type":42},{"date":368,"type":42},"2026-04-07",{"date":370,"type":23},"2027-04-17",{"name":372,"class":152},"Gan & Lee Pharmaceuticals.",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":383,"conditions":384,"keywords":389,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":50},"100624978","validation-of-hemoglobin-a1c-in-patients-with-inflammatory-arthritis-treated-with-sulfasalazine-100624978","NCT07416656","Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine","How Can We Prevent the Underdiagnosis of Diabetes and the Undertreatment of Known Diabetes in Patients With Inflammatory Arthritis Treated With Sulfasalazine?","DIA2SULFA","Inclusion Criteria:\n\n* Age ≥18 years\n* Treatment with sulfasalazine for at least 2 months prior to inclusion\n* Inflammatory arthritis diagnosis (Reumatoid Arthritis, Reaktive Arthritis, Axial spa, Psoriatic spondylitis, and Juvenil artrit)\n* HbA1c ≥38 mmol\u002Fmol obtained at least 2 months after sulfasalazine initiation OR a diabetes mellitus diagnosis (Type 1 diabetes mellitus, Type 2 diabetes mellitus, Malnutrition-related diabetes mellitus, Other specified diabetes mellitus (andre specificerede former for diabetes), and Unspecified diabetes mellitus (uspecificeret diabetes))\n* Can communicate in Danish\n* Informed consent including permission to upload glucose data and study ID to the Libreview Platform.\n\nExclusion Criteria:\n\n* Systemic treatment or local injections with glucocorticoids within the previous 2 months or planned within the following 4 weeks\n* Clinical conditions interfering with the interpretation of HbA1c expect for sulfasalazine alterations in red cell lifespan (etc. Dapson treatment)\n* Allergy towards the adhesive used in the CGM\n* Considered ineligible for participating (e.g. patients without decision-making capacity, , malignancy, terminal illness, ect.)",{"count":382,"type":23},75,"The purpose of this study is to examine whether the blood test Hemoglobin A1c (HbA1c) gives an accurate picture of blood glucose levels in patients with inflammatory arthritis who are treated with sulfasalazine. HbA1c is widely used to diagnose and monitor diabetes, but sulfasalazine can shorten red blood cell lifespan and thereby lower HbA1c values independently of actual glucose levels.\n\nThis may lead to underdiagnosis of diabetes in patients who develop diabetes during sulfasalazine treatment, and to undertreatment in patients with known diabetes due to falsely reassuring HbA1c values.\n\nThe study aims to answer two main questions:\n\n1. How many patients treated with sulfasalazine have undiagnosed diabetes despite having HbA1c values below the diagnostic threshold?\n2. Does HbA1c underestimate actual glucose levels when compared with continuous glucose monitoring (CGM) in patients with sulfasalazine-treated inflammatory arthritis, both in those with known diabetes and those that are not diagnosed with diabetes but have borderline HbA1c values (≥ 38 mmol\u002Fmol)?",[385,386,387,388,30],"Inflammatory Arthritis","Diabetes (DM)","Rheumatoid Arthritis (RA)","Type 1 Diabetes Mellitus",[390,391,392,393,394,102,313,395,286,396,397],"Validation of HbA1c","Sulfasalazine","Salazopyrin","Continuous glucose monitoring","CGM","Hemoglobin A1c","Type 1 Diabetes","Fasting blood glucose","2026-06-22",{"date":400,"type":42},"2026-06-25",{"date":402,"type":42},"2026-03-10",{"date":404,"type":23},"2026-10",{"name":406,"class":49},"Klavs Würgler Hansen",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":414,"minAge":137,"maxAge":162,"enrollmentInfo":415,"targetDuration":4,"studyType":24,"phases":416,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":50},"100643809","phase-4-pleasure-pleasing-lovers-efficacy-arousal-satisfaction-and-uptake-research-on-eroxon-100643809","NCT07636161","PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)","PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon): A Pilot Randomized Trial of Eroxon® Gel as an Adjunct to Tadalafil in Young Men With Diabetes-Associated Erectile Dysfunction","Inclusion Criteria:\n\n* Male sex at birth\n* Age 18-40 years\n* Diagnosis of type 2 diabetes mellitus\n* Diagnosis of erectile dysfunction\n* Currently prescribed tadalafil\n* Have a sexual partner willing to complete a survey\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Severe psychiatric illness that would impair participation\n* Use of nitrates or contraindications to sexual activity\n* Known allergy to Eroxon® gel components\n* Participation in another interventional sexual health study","MALE",{"count":280,"type":23},[417],"PHASE4","The purpose of this research study is to look at whether Eroxon® gel when used together with tadalafil, may help improve erectile function in men ages 18 to 40 who have type 2 diabetes.",[102,30],"2026-06-03",{"date":422,"type":42},"2026-06-09",{"date":424,"type":23},"2026-09",{"date":426,"type":23},"2027-09",{"name":428,"class":49},"University of Miami",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":24,"phases":439,"briefSummary":440,"conditions":441,"keywords":443,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":50},"100617322","side-to-side-duodeno-ileostomy-versus-semaglutide-in-adults-with-obesity-and-type-2-diabetes-100617322","NCT07317115","Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)","MAGvMED","Inclusion Criteria:\n\n* Body Mass Index (BMI) between 30 - 40 kg\u002Fm2 and qualifies for obesity treatment at the discretion of the treating investigator (i.e., must be assessed to qualify for both surgery and medication treatment to justify randomization).\n* Type 2 diabetes (T2D defined as HbA1c ≥ 6.5%).\n* Participant agrees to refrain from additional metabolic and bariatric (MBS) or reconstructive surgery that would affect body weight for the duration of the study.\n* Participant agrees to refrain from taking any additional semaglutide-containing or other GLP-1RA medication for the duration of the study, regardless of randomization assignment (i.e., Surgery or Medication).\n\nParticipant has been informed of the nature of the study and is willing and able to comply with requirements, including randomization, and provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Meets any of the contraindications for either treatment arm (Surgery: Magnet System; or Medication: semaglutide), thereby prohibiting randomization\n* Current or previous metabolic and bariatric surgery (MBS) treatment in the previous 12 months (e.g., sleeve gastrectomy, intragastric balloons, adjustable gastric banding).\n* Taking or treated with semaglutide, semaglutide-containing medications, or any other GLP-1RA medication in the previous 12 months.\n* Pregnant, lactating or planning pregnancy during the clinical study and follow-up period.\n* Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study.\n* Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, would contraindicate either treatment arm or could limit the participant's ability to participate in the clinical study or to comply with follow-up requirements.",{"count":438,"type":23},20,[99],"Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).",[442,234,30],"Obesity (Disorder)",[444,445,446],"Magnet System","Semaglutide","GT Metabolic Solutions, Inc.","2026-05-18",{"date":449,"type":42},"2026-05-19",{"date":451,"type":42},"2026-03-18",{"date":453,"type":23},"2028-06",{"name":446,"class":152},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":463,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":24,"phases":466,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":4},"100604929","implementing-who-hearts-d-guidelines-in-bangladesh-for-diabetes-control-and-prevention-100604929","NCT07155902","Implementing WHO HEARTS-D Guidelines in Bangladesh for Diabetes Control and Prevention","Leveraging Community-to-facility Service Provision to Implement the World Health Organization HEARTS-D Guidelines in Bangladesh for Improving Diabetes Control and Prevention (HEARTS-D for Bangladesh)","T2D IR","Inclusion Criteria:\n\n1. Adult individuals, ≥35 years of age,\n2. Of either sex,\n3. Long-term residents in the study area (defined by being a homeowner or a resident for at least the past three years), and\n4. Willing to provide informed consent for study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Individuals planning to migrate from the study area before completing the first 12-month follow-up period, and\n2. Individuals explicitly requesting exclusion from the study or unable to provide consent.","35 Years",{"count":465,"type":23},5000,[99],"Type-2 diabetes (T2D) is rising at an alarming rate in the low- and middle-income countries (LMIC). This rapid increase in the T2D burden has a particular impact on cities, where more than half the LMIC populations currently live and where 3 out of 4 people with T2D reside. In response to this growing global challenge, the World Health Organization (WHO) has emphasized (a) the need for an equitable and sustained improvement in the detection, treatment, and control of T2D, and (b) a rapid implementation of the WHO's evidence-based HEARTS-D module. However, currently, in most LMICs (such as Bangladesh), effective adoption of the WHO HEARTS-D module into routine urban primary care has been limited. These include suboptimal delivery mechanisms, poor uptake, weak monitoring system, and inadequate capacities. To address this, the investigators will evaluate a community-to-facility integrated strategy to implement WHO HEARTS-D module in the existing urban service delivery system in Bangladesh. First, the investigators will develop and optimize a community-to-facility integrated strategy for adopting the WHO HEARTS-D module using Implementation Mapping. Guided by this approach, the investigators will conduct mixed methods assessments to: (a) identify contextual factors, and (b) assess the implementation behavior of providers that may influence T2D care in cities. The investigators will then develop and optimize a suitable implementation strategy that can achieve high coverage, access and utilization of T2D care, specifically for urban poor populations, through iterative cycles of mixed methods qualitative assessments, implementation, and outcome measurements. For this aim, study staff will select the key stakeholders, primary care providers and CHWs as participants, based in 3 wards in Sylhet city of Bangladesh. Second, the investigators will evaluate the impacts of the optimized community-to-facility integrated strategy on implementation outcomes. The investigators will conduct a 2-arm, type 2, hybrid implementation-effectiveness randomized trial. The study will involve 20 municipal wards as clusters from Sylhet city (10 in each arm). This study compare the following strategies: (a) a community-to-facility integrated strategy for implementing the WHO HEARTS-D module and (b) a facility-only usual service delivery. The investigators will evaluate the implementation process by relevant outcomes based on the RE-AIM framework components: reach, effectiveness, implementation, and maintenance. Third, the investigators will compare the effectiveness of this strategy on T2D status. In a study sample of 10,000 randomly selected participants, the investigators will compare improvements in the prevalence of controlled T2D, treatment uptake and adherence to glucose-lowering therapy, T2D complications and awareness among participants in both study arms from baseline to end-line. Our study should guide the policymakers into effective implementation and sustainment of WHO HEARTS-D module that can be: (a) embedded within local organizational structures, and (b) adapted to similar contexts globally.",[30],[461,470,102,471,472],"HEARTS-D","Implementation Research","Non-communicable disease (NCD)","2026-05-07",{"date":475,"type":42},"2026-05-08",{"date":477,"type":23},"2026-07",{"date":479,"type":23},"2029-09",{"name":481,"class":49},"Florida International University",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":492,"briefSummary":493,"conditions":494,"keywords":499,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":504,"leadSponsor":505,"locationsCount":4},"100596312","impact-of-pharmate-trial-on-glycemic-control-diabetes-knowledge-medication-adherence-and-quality-of-life-in-type-2-diabetes-patients-a-mixed-method-study-protocol-100596312","NCT07043816","Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol","PharmaTE","Inclusion Criteria\n\n* Patients diagnosed with uncontrolled type 2 diabetes (defined as glycated haemoglobin \\[HbA1c\\] \\>7%) within the previous 12 months\n* Adults (18 to 65 years) of either gender\n* Prescribed at least one antidiabetic medication\n* Have access to either a telephone or a mobile phone\n* Treated in an outpatient facility in IBOH, RAK\n* Arabic-speaking patients\n* Patients who understand study information and are given written informed consent.\n\nExclusion Criteria:\n\n* Under 18 years old\n* Pregnant ladies\n* Patients admitted to the emergency department\n* Patients with severe hepatic or renal dysfunction\n* Diagnosed with type 1 DM or diagnosed with gestational diabetes\n* Having vision or hearing impairments and psychological problems\n* Immunocompromised patients, e.g., organ transplants, AIDS, cancer patients, and patients on immunosuppressant therapy\n* Patients with no or limited access to either a telephone or mobile phone, as well as those without reliable internet access","65 Years",{"count":491,"type":23},154,[99],"The goal of this clinical trial is to find out whether a pharmacist-led tele-educational program (PharmaTE trial) can help people with type 2 diabetes manage their condition better.\n\nThe main questions this study aims to answer are:\n\n1. Does the PharmaTE trial improve blood sugar control (HbA1c levels)?\n2. Does it help patients better understand their condition?\n3. Does it increase how well patients follow their medication schedule?\n4. Does it improve the quality of life for patients with type 2 diabetes?\n5. Is this type of tele-education program feasible and acceptable for patients?\n\nParticipants will:\n\nBe randomly placed into one of two groups:\n\nIntervention group: Receive five virtual education sessions with a clinical pharmacist over the phone or via Zoom (each lasting 20-30 minutes), in addition to their usual diabetes care.\n\nControl group: Continue receiving standard diabetes care from their healthcare team without the additional pharmacist-led sessions.\n\nComplete assessments at the beginning and end of the study. These include:\n\nA blood test for HbA1c\n\n, Questionnaires on diabetes knowledge, medication adherence, and quality of life\n\nSome participants in the intervention group will be invited for interviews after the sessions to share their experiences and opinions about the program.\n\nWho can join? Adults aged 18-65 with uncontrolled type 2 diabetes (HbA1c \\> 7%), receiving care at Ibrahim Bin Hamad Obaidullah Hospital in Ras Al-Khaimah, who speak Arabic and can provide consent.",[30,495,496,497,498],"Glycemic Control","Diabetes Knowledge","Medication Adherence","Quality of Life",[487],"2026-04-28",{"date":502,"type":42},"2026-04-29",{"date":322,"type":23},{"date":217,"type":23},{"name":506,"class":49},"Rabia Hussain",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":161,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":24,"phases":515,"briefSummary":516,"conditions":517,"keywords":523,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":50},"100634680","using-virtual-reality-to-improve-medical-training-100634680","NCT07542834","Using Virtual Reality to Improve Medical Training","Enhancing Osteopathic Medical Education Through Cinematic Virtual Reality","Inclusion Criteria: able to read and speak English, are age 18 years and older, and are a medical student enrolled at the Ohio University Heritage College of Osteopathic Medicine enrolled in the 2025-2026 academic year.\n\n\\-\n\nExclusion Criteria: unable to read and speak English, 17 years or younger, and are not a medical student enrolled at the Ohio University Heritage College of Osteopathic Medicine enrolled in the 2025-2026 academic year.\n\n\\-",{"count":22,"type":23},[99],"As the U.S. population ages, future physicians must be prepared to care for older adults with multiple health conditions and complex needs. This study will test whether cinematic virtual reality (VR)-an immersive, interactive learning tool-is more effective than traditional lectures in helping medical students learn about geriatric care. Students who complete the VR training will experience realistic patient scenarios that show what can go wrong in medical care and learn how to apply osteopathic principles to improve outcomes. Researchers will compare students' performance on a clinical skills assessment and explore their experiences with the VR training. The goal is to determine whether cinematic virtual reality can better prepare students for residency and improve their ability to provide compassionate, high-quality care for older adults.",[30,518,519,520,521,522],"Geriatric Syndromes","Disability Hearing","Disability Physical","Urinary Tract Infection(UTI)","Delirium Confusional State",[524],"virtual reality, type 2 diabetes, geriatric syndromes, disability, elder abuse and neglect","2026-04-14",{"date":527,"type":42},"2026-04-21",{"date":529,"type":23},"2026-04-15",{"date":531,"type":23},"2027-06-30",{"name":533,"class":49},"Ohio University",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":138,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":50},"100622698","phase-2-evaluate-the-efficacy-and-safety-of-gzr101-80-injection-in-patients-with-type-2-diabetes-100622698","NCT07387003","Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","A Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs or Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin","Inclusion Criteria:\n\n1. Subjects sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and are able to follow the contraindications and restrictions specified in this protocol.\n2. At the age of 18-75 (inclusive) at the time of informed consent, male or female.\n3. Body mass index (BMI) ≥18.5 and ≤35.0 kg\u002Fm2 at screening.\n4. According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening.\n\nExclusion Criteria:\n\n1. Confirmed or suspected type 1 diabetes mellitus or specific types of diabetes due to other causes (monogenic diabetes, cystic fibrosis, pancreatitis, drug- or chemical-induced diabetes, etc.) prior to screening.\n2. Grade 3 hypoglycemia within 3 months before screening.\n3. Subjects who have any diseases that may affect HbA1c testing at screening, or subjects who have donated blood, lost more than 400 mL of blood, or received blood transfusion within 3 months prior to screening.\n4. Diagnosis of active malignant tumor within 5 years prior to screening (excluding adequately treated or resected non-metastatic basal or squamous cell skin cancer, in situ cancer of cervix, or prostate cancer in situ), or with a high suspicion of potential malignant tumor at screening.",{"count":542,"type":23},345,[309],"This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.",[30],"2026-04-10",{"date":529,"type":42},{"date":546,"type":23},{"date":550,"type":23},"2027-09-23",{"name":372,"class":152},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":24,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":438},"100609824","phase-3-a-study-to-evaluate-the-effect-of-obicetrapibezetimibe-10-mg-fixed-dose-combination-or-obicetrapib-10-mg-daily-on-top-of-guideline-recommended-lipid-lowering-therapy-in-participants-with-type-2-diabetes-andor-metabolic-syndrome-100609824","NCT07219602","A Study to Evaluate the Effect of Obicetrapib\u002FEzetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome","A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome (RUBENS Trial)","RUBENS","Inclusion Criteria:\n\n* fasting serum LDL-C ≥ 70 mg\u002FdL (≥1.81 mmol\u002FL)\n* Have fasting TG ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL)\n* Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg\u002FdL (≥1.7mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL) and at least 2 risk factors\n* Are on stable guideline-recommended lipid-lowering therapy\n* Estimated glomerular filtration rate ≥15 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \\\u003C30%\n* Have been hospitalized for heart failure within 5 years prior to Screening\n* Have uncontrolled severe hypertension\n* Have a formal diagnosis of homozygous familial hypercholesterolemia\n* HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg\u002FdL (≥15.0 mmol\u002FL) at Screening\n* active liver disease",{"count":561,"type":23},300,[26],"This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and\u002For Type 2 Diabetes Mellitus.",[565,30,566],"Lipidemia","Metabolic Syndrome (MetS)","2026-03-06",{"date":402,"type":42},{"date":570,"type":42},"2025-12-11",{"date":453,"type":23},{"name":573,"class":152},"NewAmsterdam Pharma",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":161,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":580,"targetDuration":582,"studyType":63,"phases":4,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":50},"100626555","the-establishment-of-hong-kong-diabetes-steatotic-liver-disease-register-100626555","NCT07437157","The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register","Inclusion Criteria:\n\n* T2DM.\n* Aged ≥ 18 years.\n* Able and willing to give Informed written consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* Terminal illness such as malignancy with limited life expectancy.\n* Any condition, as judged by the investigators, as ineligible to participate in this study.",{"count":581,"type":23},1000,"15 Years","Liver is an important organ in maintaining energy homeostasis. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease locally and globally. MASLD and type 2 diabetes mellitus (T2DM) are closely related with alarmingly high prevalence of MASLD in people with T2DM, along with the escalated risk of adverse clinical outcomes. Our group has reported that around 70% of people with T2DM have increased controlled attenuation parameter (CAP) suggestive of hepatic steatosis and one out of six had advanced liver fibrosis as evidenced by increased liver stiffness measurements (LSM). Despite its prevalence, close relationships and potential consequences, the mechanisms underlying the complex interconnections between MASLD and T2DM are not fully understood. MASLD is associated with a twofold higher risk of developing T2DM, independent of obesity and other common metabolic risk factors. This risk increases with the severity of MASLD, such that patients with more advanced stages of liver fibrosis are at a higher risk of developing T2DM. Moreover, the progression from hepatic steatosis to fibrosis is an important, yet not fully understood, step towards cirrhosis and end-stage liver disease. Identification of clinical predictors and biomarkers to select individuals with MAFLD for close monitoring is pivotal to prevent the sinister outcomes. To date, longitudinal cohorts with paired biobank focused on people with diabetes and comorbid MASLD for investigating the clinical courses and biomarkers for prediction of outcomes are lacking. We hypothesized that Hong Kong Chinese T2DM with comorbid steatotic liver disease have unique clinical courses and special biomarkers for predicting the progression to advanced liver fibrosis. The aims of this study are: 1) establish a prospective cohort of people with T2DM and comorbid steatotic liver disease accompanied with the setting up of a biobank; 2) elucidate the clinical courses and outcomes of Hong Kong Chinese T2DM with comorbid steatotic liver disease; 3) identify potential diagnostic markers of advanced liver fibrosis in people with T2DM and comorbid steatotic liver disease in Hong Kong. The primary outcome measure will be all-cause mortality and secondary outcome measure will be fatal and non-fatal CVD, heart failure, hospitalizations, NT-proBNP levels, and novel diagnostic markers of MASH in people with T2DM comorbid with MASLD.",[262,30],"2026-02-25",{"date":587,"type":42},"2026-02-27",{"date":589,"type":42},"2025-06-11",{"date":591,"type":23},"2027-02-28",{"name":593,"class":49},"Chinese University of Hong Kong",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":95,"enrollmentInfo":601,"targetDuration":4,"studyType":24,"phases":603,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":50},"100611887","glucagon-resistance-in-patients-with-masld-and-t2dm-100611887","NCT07246421","Glucagon Resistance in Patients With MASLD and T2DM","Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 Diabetes","Inclusion Criteria:\n\n* BMI \\> 26 kg\u002Fm²\n* confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) min. 6 months prior enrollment\n* steatosis FF% \\> 5,6% on MR spectroscopy for MAFLD group\n\nExclusion Criteria:\n\n* Alcohol abuse (\\>10 units per week for both sexes) or other substance abuse\n* Smoking\n* Current or previous malignant disease\n* Blood donation within the last 3 months prior to the study day\n* Participation in studies involving radioactive isotopes within the past 3 months\n* Pregnancy\n* Severely dysregulated type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol\u002Fmol)\n* C-peptide \\\u003C 200 pmol\u002FL\n* Previous acute myocardial infarction (AMI)\n* Clinical symptoms of heart failure\n* Current or previous malignant disease\n* Known ongoing systemic disease, except for dyslipidaemia and hypertension\n* Regular use of medication that may affect lipid and glucose metabolism, including insulin treatment, regular use of over-the-counter medications, and hormonal contraception. Exceptions:\n\n  1. Participants treated with statins may be included following a 2-week washout period prior to the experimental study day.\n  2. Participants receiving oral glucose-lowering therapy for T2DM and antihypertensive medication may be included provided that medication is withheld on the study day only.\n  3. Participants receiving weekly injectable glucagon-like peptide-1 receptor agonists (GLP-1 analogues) may be included following a 1-week washout period prior to the study day.",{"count":602,"type":23},24,[99],"The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).\n\nThe main questions it aims to answer are:\n\n1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD?\n2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic\u002Fmetabolomic profile in blood and adipose tissue?\n\nResearchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups.\n\nParticipants will attend 2 short visits and 1 full-day visit, including:\n\n* Body scan (DXA) to check fat and bone composition\n* MRI to measure liver fat.\n* Blood tests.\n* Ultrasound to check liver stiffness and scarring.\n* Fat biopsies\n* 8-hour hormone (including glucagon) and tracer infusion\n* PET-CT scans",[606,30],"Metabolic Associated Fatty Liver Disease",[608,609,610],"MASLD","Glucagon","Glucagon Resistance","2026-02-03",{"date":613,"type":42},"2026-02-04",{"date":615,"type":42},"2026-01-29",{"date":617,"type":23},"2028-07-31",{"name":619,"class":49},"University of Aarhus",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":629,"conditions":630,"keywords":633,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":50},"100614969","sexual-activity-and-hypoglycemia-risk-in-adults-with-type-1-or-type-2-diabetes-using-insulin-therapy-and-continuous-glucose-monitoring-100614969","NCT07286500","\"Sexual Activity and Hypoglycemia Risk in Adults With Type 1 or Type 2 Diabetes Using Insulin Therapy and Continuous Glucose Monitoring\"","\"Impact of Sexual Activity on Hypoglycemia Risk in Adults With Type 1 and Type 2 Diabetes Under Insulin Therapy and Continuous Glucose Monitoring (CGM)\"","SEX-HYPO-CGM","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosis of type 1 or type 2 diabetes.\n* Current use of a continuous glucose monitoring (CGM) system.\n* Treatment with insulin therapy in any regimen.\n* Ability to operate the CGM application and mark the start of sexual activity.\n* Willingness to participate for 3 months.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Inability to independently use the CGM application.\n* No sexual activity during the study period.\n* Withdrawal of consent at any time.\n* Any condition that, in the opinion of the investigator, prevents safe participation.",{"count":22,"type":23},"This observational study examines whether sexual activity influences the risk of hypoglycemia in adults with type 1 or type 2 diabetes treated with insulin therapy and using continuous glucose monitoring (CGM). Many patients report fear of hypoglycemia during or after sexual activity, which may affect their quality of life and willingness to engage in intimate relationships. However, no systematic research has been conducted on this topic, largely due to the sensitive nature of sexual health and the previous lack of tools to remotely monitor glucose profiles.\n\nThe study uses CGM systems (LibreView or Dexcom Clarity) to evaluate glucose changes during and up to 6 hours after sexual activity. Participants will mark the start of sexual activity in their CGM application using a neutral symbol (such as a heart icon). Data will be collected remotely through secure, certified platforms without the need for discussing details of intimate life. Glucose profiles from days with and without sexual activity will be compared. Each participant will be observed for 3 months.\n\nThe study will include 100 adults with type 1 or type 2 diabetes who use CGM and insulin therapy. By analyzing episodes of glucose levels below 70 mg\u002FdL during or after sexual activity, the study aims to determine whether sexual activity is associated with an increased risk of hypoglycemia. Findings may help to better understand patient concerns, reduce unnecessary fear, and develop future clinical recommendations for safe sexual activity in individuals treated with insulin.",[631,30,632],"Type 1 Diabetes (T1D)","Hypoglycemia",[634,632,635,72,394,636,396,102,637],"Sexual Activity","Glucose Variability","Insulin Therapy","Diabetes Complications","2025-12-02",{"date":640,"type":42},"2025-12-16",{"date":642,"type":42},"2025-07-30",{"date":644,"type":23},"2028-07-10",{"name":646,"class":49},"Medical University of Warsaw",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":161,"sex":18,"minAge":137,"maxAge":205,"enrollmentInfo":653,"targetDuration":4,"studyType":24,"phases":655,"briefSummary":656,"conditions":657,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":663,"leadSponsor":665,"locationsCount":50},"100610486","role-of-endothelial-dysfunction-on-exercise-pressor-reflex-in-type-2-diabetes-100610486","NCT07228208","Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes","Inclusion Criteria:\n\n* Type 2 Diabetes: 18 - 80 years old, able to give informed consent, \\> 6 months post-diagnosis, \\> 6 months stable medications for management\n* Healthy controls: 18 - 80 years old, able to give informed consent\n\nExclusion Criteria:\n\n* Type 2 Diabetes: Type 1 diabetes, symptomatic coronary artery disease, cardiovascular event in last year (MI, stroke), uncontrolled or unmanaged hypertension (\\>160\u002F90 mmHg), heart failure, renal impairments, current or recent (\\\u003C6 months) tobacco use, hormone replacement therapy, documented neuromuscular disorders, pregnancy\n* Healthy Controls: Same as listed in Type 2 Diabetes with Type 2 Diabetes as an exclusion factor",{"count":654,"type":23},40,[99],"Exaggerated blood pressure responses to exercise in individuals with Type 2 Diabetes significantly increase the risk of heart attack, stroke, and cardiovascular death, while also limiting exercise capacity and therapeutic benefits of physical activity. This research will determine whether impaired blood vessel function and excessive cellular damage from oxygen-containing molecules cause these dangerous blood pressure responses during exercise. The findings will establish whether targeting cellular antioxidant systems represents a new therapeutic approach to improve exercise tolerance and reduce cardiovascular risk in t Americans living with diabetes.",[30,658],"Endothelial Dysfunction","2025-11-12",{"date":661,"type":42},"2025-11-14",{"date":322,"type":23},{"date":664,"type":23},"2031-12-31",{"name":666,"class":49},"Medical College of Wisconsin",{"id":668,"slug":669,"hasResults":12,"nctId":670,"briefTitle":671,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":138,"enrollmentInfo":674,"targetDuration":4,"studyType":24,"phases":676,"briefSummary":677,"conditions":678,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":687},"100597899","phase-3-a-study-of-bgm0504-in-participants-with-type-2-diabetes-in-indonesia-100597899","NCT07064486","A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia","A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* ○ Have been diagnosed with type 2 diabetes mellitus (T2DM);\n\n  * Be on stable treatment with unchanged dose of metformin ≥1500 mg\u002Fday or \\\u003C1500 mg\u002Fday but ≥1000 mg\u002Fday (the maximum tolerated dose) for at least 8 weeks prior to screening\n  * Have a BMI ≥23 kilograms per meter squared (kg\u002Fm²) at screening;\n  * Be of stable weight (± 5%) for at least 3 months before screening;\n  * Have HbA1c between ≥7.5% and ≤11.0% at screening\n\nExclusion Criteria:\n\n* ○ Previous diagnosis of type 1 diabetes, special type diabetes;\n\n  * Have suffered the malignancy within the past 5 years (except cured basal cell carcinoma of the skin, cervical carcinoma in situ), or being evaluated for an underlying malignancy;\n  * Have the acute or chronic pancreatitis;\n  * Known to be allergic to 3 or more kinds of foods or medications, or allergic to GLP-1 agonist or metformin, or have a severe allergic disease (asthma, urticaria, eczematous dermatitis, etc.) at screening;\n  * Have a serious mental illness or speech impediment and be unable to fully understand the study;\n  * Suspected or confirmed history of alcohol or drug abuse;\n  * Have had a history of ≥2 severe hypoglycemic episodes in the past 1 year;\n  * Other conditions that may impact the assessment of investigational products, as determined by the Investigator.",{"count":675,"type":23},477,[26],"This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes",[30],"2025-10-27",{"date":681,"type":42},"2025-10-28",{"date":683,"type":42},"2025-07-04",{"date":685,"type":23},"2026-07-31",{"name":151,"class":152},4]